



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Piclidenoson

Cat. No.:	HY-13591
CAS No.:	152918-18-8
Molecular Formula:	C ₁₈ H ₁₉ IN ₆ O ₄
Molecular Weight:	510.29
Target:	Adenosine Receptor; Apoptosis
Pathway:	GPCR/G Protein; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 45 mg/mL (88.19 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9597 mL	9.7983 mL	19.5967 mL
	5 mM		0.3919 mL	1.9597 mL	3.9193 mL
	10 mM		0.1960 mL	0.9798 mL	1.9597 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.90 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19^{[1][2][3][4]}.

IC₅₀ & Target

A3AR^[2]

In Vitro

Piclidenoson is able to inhibit Forskolin (HY-15371)-stimulated cAMP levels with EC₅₀s of 0.82 μ M and 1.2 μ M in OVCAR-3 cells and Caov-4 cells, respectively^[2].

Piclidenoson (0.0001-100 μ M; 48 hours) significantly reduces cell viability in a dose-dependent manner in human ovarian cancer cell lines, with IC₅₀s of 32.14 μ M and 45.37 μ M for OVCAR-3 and Caov-4 cells, respectively^[2].

Piclidenoson (0.001-100 μ M; 48 hours) induces apoptosis in ovarian cancer cell line through the caspase pathway^[2].

Piclidenoson induces apoptosis via the mitochondrial signaling pathway^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:	OVCAR-3 cells, Caov-4 cells
Concentration:	0.0001-100 μ M
Incubation Time:	48 hours
Result:	Resulted in a dose-dependent reduction in the cell viability.

Apoptosis Analysis^[2]

Cell Line:	OVCAR-3 cells, Caov-4 cells
Concentration:	0.1 μ M, 1 μ M, 10 μ M, 50 μ M, 100 μ M
Incubation Time:	48 hours
Result:	Significant increased in the percentage of apoptosis in a concentration-dependent manner.

Western Blot Analysis^[2]

Cell Line:	OVCAR-3 cells, Caov-4 cells
Concentration:	1 μ M, 10 μ M, 100 μ M
Incubation Time:	48 hours
Result:	Decreased the expression of Bcl-2 was noticeably and increased the expression of Bax protein.

In Vivo

Piclidenoson (105 μ g/kg; i.p.) enhances survival of γ -irradiated mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	B10CBAF1 male mice aged 3 months (average 30 g) ^[1]
Dosage:	105 μ g/kg
Administration:	Intraperitoneal injection, 0.5 h after irradiation
Result:	Resulted in statistically significant increases of the mean survival time in comparison with the control irradiated mice.

CUSTOMER VALIDATION

- Cancers (Basel). 2022, 14(23), 5854

-
- Bone. 2021 Nov 23;116264.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hofer M, et al. Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ -irradiated mice. *Radiat Environ Biophys*. 2014 Mar;53(1):2
- [2]. Abedi H, et al. Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines. *Tumour Biol*. 2014 Nov;35(11):11027-11039.
- [3]. Shin Y, et al. Activation of Phosphoinositide Breakdown and Elevation of Intracellular Calcium in a Rat RBL-2H3 Mast Cell Line by Adenosine Analogs: Involvement of A(3)-Adenosine Receptors? *Drug Dev Res*. 1996 Sep 1;39(1):36-46.
- [4]. Chandan Sarkar, et al. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives. *Front Pharmacol*. 2020; 11: 572870.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA